Long-Term Changes in Complete Blood Count-Derived Inflammatory Indices During Risankizumab Treatment for Psoriasis: A 208-Week Multicenter Real-World Study.
Balestri R, Pallanch C, Magnano M, Colombini J, Clarizio G, Bardazzi F, Di Lernia V, Satolli F, Ganzetti G, Buligan C, Mazzoletti V, Pacetti L, Odorici G, Borghi A, Saraceno R, Mengarino M, Gisondi P, Girolomoni G, Lacava R, Rech G, Bellinato F